Contact No: +91-8826373757 | +91-8826859373 | 011-25052216
Email: rakesh.its@gmail.com | editor@innovativepublication.com


Article Access statistics

Viewed: 161

Emailed: 0

PDF Downloaded: 43

Current Opinion in Virus and Infectious Diseases - COVID


Empirical pharmacotherapy of COVID-19


Full Text PDF Share on Facebook Share on Twitter


Review Article

Author Details : R Arbind Kumar Choudhary*, L Madhan, R Mani, Isaac Christians Moses

Volume : 1, Issue : 2, Year : 2020

Article Page : 23-27


Suggest article by email

Abstract

Researchers are studying several types of drugs to treat the novel coronavirus or COVID-19 that has spread to over 200 countries, taking a massive human toll of nearly 2.6 lakh as of Wednesday morning. About 37 lakh positive cases have been identified, including almost 50,000 cases in India. Most drugs being worked upon are repurposed and are largely anti-viral drugs used previously to treat other conditions. For instance, Favipiravir, or Avigan was used to treat influenza in Japan. Likewise, Remdesivir was tested on Ebola. Another treatment, while not a drug, that has shown promise is plasma therapy. The method uses convalescent plasma which is extracted from the blood of recovered COVID-19 patients. This plasma contains antibodies that neutralize SARS-CoV-2.Hydroxychloroquine and Chloroquine have not been shown to be safe and effective for treating or preventing COVID-19. They are being studied in clinical trials for COVID-19, and temporary use during the COVID-19 pandemic for treatment of the virus in hospitalized patients

Keywords: Empirical Pharmacotherapy, COVID-19, Remdesivir, Favipiravir, Chloroquine.

Doi : 10.18231/j.ijirm.2020.021

How to cite : Choudhary R A K, Madhan L, Mani R, Moses I C, Empirical pharmacotherapy of COVID-19. Covid-19 2020;1(2):23-27

Copyright © 2020 by author(s) and Covid-19. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (creativecommons.org)